Table 3 Subgroup analyses for serious respiratory tract infection.
Treatment | No. of studies | With PAH-specific therapy | With placebo therapy | Total | RR | 95%CI (p value) | Homogeneity | |
|---|---|---|---|---|---|---|---|---|
I 2 (%) | p value | |||||||
Class of PAH-specific drugs | ||||||||
Prostanoids | 5 | 8/627(1.3%) | 9/540(1.7%) | 17/1167(1.5%) | 0.66 | 0.28–1.57(0.35) | 20.4 | 0.29 |
ERAs | 7 | 52/899(5.8%) | 29/554(5.2%) | 81/1453(5.6%) | 1.20 | 0.78–1.83(0.40) | 0 | 0.64 |
PDE5 inhibitors | 2 | 18/341(5.3%) | 18/201(9.0%) | 36/542(6.6%) | 0.93 | 0.51–1.70(0.81) | 0 | 0.95 |
sGCs | 3 | 8/502(1.6%) | 2/220(0.9%) | 10/722(1.4%) | 1.54 | 0.38–6.26(0.55) | 0 | 0.92 |
Selective prostacyclin receptor agonist | 2 | 43/608(7.1%) | 47/587(8.0%) | 90/1195(7.5%) | 0.90 | 0.61–1.33(0.60) | 44.7 | 0.18 |
Monotherapy or combination therapy | ||||||||
Monotherapy vs. Placebo | 8 | 16/787(2.0%) | 10/369(2.7%) | 26/1156(2.2%) | 0.76 | 0.37–1.56(0.45) | 0 | 0.72 |
combination therapy vs. Monotherapy | 12 | 139/2493(5.6%) | 143/2337(6.1%) | 282/4830(5.8%) | 1.04 | 0.83–1.30(0.75) | 0 | 0.71 |
